El interés en corto de DBV Technologies da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de DBV Technologies. Los datos de interés en corto se actualizan cada dos semanas.

DBV Technologies (NASDAQ:DBVT) Bolsa, Informe de interés en corto

DBV TECHNOLOGIES SA-SPON ADR

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 105.9% to $9.7 during Friday's regular session. The company's market cap stands at $15.9 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares rose 78.39% to $0.62. The company's market cap stands at $224.1 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 40.92% to $5.51. The market value of their outstanding shares is at $113.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 29.3% to $0.56. The market value of their outstanding shares is at $14.0 million. As per the press release, Q4 earnings came out today. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares moved upwards by 14.24% to $0.88. The market value of their outstanding shares is at $23.5 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 14.09% to $0.78. The company's market cap stands at $42.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 72.5% to $0.04 during Friday's regular session. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares declined by 60.37% to $0.89. The market value of their outstanding shares is at $47.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 51.28% to $0.02. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 29.73% to $1.6. The company's market cap stands at $18.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 27.68% to $2.64. The company's market cap stands at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 26.02% to $25.8. The market value of their outstanding shares is at $335.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DBVT

LGMK

LXRX

MIST

PRLD

PRTG

SNSE

STSS

VERO

12 Health Care Stocks Moving In Friday's Intraday Session

DBV Technologies SA &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>), a clinical-stage biopharmaceutical company focused on pediatric allergies, <a href="https://www.benzinga.com/pressreleases/25/03/g44528665/dbv-technologies-announces-financing-of-up-to-306-9-million-284-5-million-to-advance-viaskin-peanu">announced a financing deal</a> of up to $306.9 million (€284.5 million). The stock is up some 50% to $5.90 during Friday&#8217;s session following the deal.
What To Know: The company will receive $125.5 million (€116.3 million) upon closing, with an additional $181.4 million (€168.2 million) possible if all warrants are exercised.
The funding will support working capital, the Viaskin Peanut program, a potential Biologics License Application, and a U.S. launch if approved. The financing, led by major healthcare investors, could dilute existing shareholders by up to 73.7%. 
CEO Daniel Tassé highlighted the company's alignment with the FDA on safety data, potentially expediting the BLA submission. The Phase 3 VITESSE study, exceeding enrollment expectations, aims for results in fourth-quarter 2025.
Read Also: <a href="https://www.benzinga.com/news/25/03/44539023/whats-going-on-with-ford-stock-2">What&#8217;s Going On With Ford Stock?</a>
<h2 class="wp-block-heading">How To Buy DBVT Stock</h2>
By now you're likely curious about how to participate in the market for DBV Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DBVT has a 52-week high of $8.32 and a 52-week low of $2.20.

News

Why DBV Technologies (DBVT) Stock Is Skyrocketing

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 500 points on Friday.
The Dow traded down 1.21% to 41,788.66 while the NASDAQ fell 2.11% to 17,424.77. The S&amp;P 500 also fell, dropping, 1.49% to 5,608.74.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 1.2% on Friday.
In trading on Friday, consumer discretionary shares fell by 2.8%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 126% to $10.67 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Abacus Global Management, Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NYSE">ABL</a>)got a boost, surging 13% to $8.11 following strong quarterly sales.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 48% to $6.00 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 62% to $0.8550 after the company received a letter from the FDA for its new drug application for CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.29 after the company priced its public offering at $1.36 per share.</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) was down, falling 16% to $57.37 after the company reported a third-quarter sales miss.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $69.76 while gold traded up 0.7% at $3,112.20.
Silver traded up 0.7% to $35.340 on Friday, while copper rose 0.7% to $5.1545.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 declined 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate. </li>
<li>The University of Michigan consumer sentiment fell to 57 in March versus a preliminary reading of 57.9.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

XTIA

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.24% to 42,198.64 while the NASDAQ fell 0.57% to 17,701.94. The S&amp;P 500 also fell, dropping, 0.36% to 5,672.68.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 0.6% on Friday.
In trading on Friday, consumer discretionary shares fell by 1.4%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 170% to $12.79 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)got a boost, surging 83% to $0.6359 after the company announced an exclusive license agreement with Novo Nordisk for LX9851.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 43% to $5.79 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 64% to $0.7997 after the company received a letter from the FDA for its new drug applicationfFor CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.2689 after the company priced its public offering at $1.36 per share.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) was down, falling 41% to $3.18. On Thursday, Wolfspeed announced the appointment of Robert Feurle as CEO, effective May 1, 2025.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.82 while gold traded up 0.5% at $3,106.80.
Silver traded up 0.5% to $35.255 on Friday, while copper rose 0.5% to $5.1440.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>

WOLF

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected

WIIM

DBV Technologies shares are trading higher after the company announced up to $307 million in financing to advance the Viaskin Peanut program.

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock rose 158.8% to $12.19 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock rose 106.53% to $0.72. The company's market cap stands at $259.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 61.12% to $6.3. The company's market cap stands at $129.2 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 17.14% to $0.8. The company's market cap stands at $44.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 15.59% to $0.6. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 15.51% to $1.02. The company's market cap stands at $16.9 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) stock fell 61.8% to $0.86 during Friday's pre-market session. The company's market cap stands at $45.8 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares declined by 24.12% to $0.04. The market value of their outstanding shares is at $1.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock decreased by 24.0% to $0.19. The company's market cap stands at $1.3 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares decreased by 20.43% to $1.13. The company's market cap stands at $6.1 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock fell 20.26% to $3.11. The company's market cap stands at $117.1 million. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) shares declined by 16.23% to $3.51. The company's market cap stands at $199.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DRMA

DSGN

IRIX

PTIX

RNAZ

SERA

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of major benchmark indices were lower in premarket trading.
Stocks slid as investors digested the new auto tariffs levied on foreign cars and auto parts.
President Donald Trump also warned that he would impose much higher tariffs on the EU and Canada if they retaliate against his planned tariffs.
In a Truth Social post, he threatened large-scale tariffs to counter any economic harm from the two allies. While he has recently hinted at targeting them in his upcoming "Liberation Day" tariffs, no direct actions have been taken yet.
Traders will watch out for the Federal Reserve&#8217;s preferred measure of inflation, the Personal Consumption Expenditures Price Index, specifically the core PCE, which excludes food and energy prices due to their volatility.
With the 10-year Treasury yield at 4.32% and the 2-year at 3.99%, the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in an 88.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.40%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.22%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.15%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.12%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Friday. The SPY was down 0.19% to $565.98, while the QQQ declined 0.36% to $479.89, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Most sectors on the S&amp;P 500 ended in the red on Thursday, with energy, communication services, and information technology stocks leading the losses. However, health care and consumer staples stocks managed to buck the trend, closing higher.
European automakers were hit hard, with Mercedes-Benz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>) sliding 1.7% and Porsche Automobil Holding SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/POAHF#OTC">POAHF</a>) dropping 2.3%.
In earnings news, shares of TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) tumbled around 14% after the company reported its first-quarter results. Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) also fell sharply, dropping more than 13% following worse-than-expected fourth-quarter earnings and weaker-than-expected FY26 EPS guidance.
On the economic front, U.S. initial jobless claims dipped by 1,000 to 224,000 for the week ending March 22, slightly below market estimates of 225,000. Meanwhile, fourth-quarter GDP growth was revised up to an annualized 2.4% from 2.3%, and U.S. wholesale inventories increased by 0.3% in February, following a 0.8% gain in January.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.53%</td>
<td>17,804.03</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.33%</td>
<td>5,693.31</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.37%</td>
<td>42,299.70</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.39%</td>
<td>2,065.70</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to the analysts at BlackRock, the weight of non-U.S. equities in global equity indexes has been on the rise since the end of January. This is caused by the policy uncertainty, which has shaken the investor belief in the U.S. growth and equity strength, pulling the S&amp;P 500 down more than 3%, the note added.
&#8220;The selloff has been exacerbated by investors rapidly pulling out of popular trades – like the tech-heavy momentum equity style factor and cyclical trades that were betting on a boost from growth from potential U.S. deregulation and tax cuts.&#8221;
&#8220;We stay overweight U.S. stocks on a six- to 12-month tactical horizon. Yet prolonged uncertainty could hurt both U.S. and global risk assets,&#8221; the note adds.
Meanwhile, as the uncertainty around tariffs mounts, Michael Townsend, managing director of legislative and regulatory affairs with Schwab, said that &#8220;The White House has been sending mixed signals.&#8221;
&#8220;First, saying that they would be imposed on all countries, then more recently saying they will initially focus on 10 to 15 countries with which the U.S. has big trade deficits. The plan also was to announce tariffs on automobiles, pharmaceuticals, and semiconductors next week, but those reportedly will be delayed. The uncertainty is driving companies and investors crazy.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>Personal income, spending, personal consumption expenditure index, and core PCE index are scheduled to be released at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Consumer sentiment data is scheduled to be released at 10 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Super League Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) jumped 7.32% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly loss of 26 cents per share on the revenue of $5.50 million.</li>
</ul>
<ul>
<li>Katapult Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) was down 2.16% as Wall Street expects it to report a quarterly loss of $1.77 per share on revenue of $62.20 million before the opening bell.</li>
</ul>
<ul>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) slumped 10.84% as it sees full-year 2025 earnings in the range of $14.95 to $15.15 per share, versus estimates of $15.30 per share.</li>
</ul>
<ul>
<li>Braze Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) surged 10.63% after it reported better-than-expected fourth-quarter financial results and issued strong FY26 adjusted EPS guidance.</li>
</ul>
<ul>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) was up 2.41% after posting upbeat earnings for the third quarter, while sales missed estimates.</li>
</ul>
<ul>
<li>Direct Digital Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) plunged 38.35% after it reported a substantial earnings miss in the fourth quarter, with earnings per share of -$0.54, sharply below the forecasted $0.11.</li>
</ul>
<ul>
<li>XTI Aerospace Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) dropped 31.30% after announcing a public offering of common stock and warrants; the offering&#8217;s size and valuation remain undisclosed. Proceeds will repay debt and fund operations. This move follows a recent $5 million share buyback.</li>
</ul>
<ul>
<li>Dermata Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) plummeted 21.13% as it announced an agreement for the exercise of 4,834,470 outstanding warrants at a reduced price of $1.284 per share.</li>
</ul>
<ul>
<li>Sensei Biotherapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) climbed 26.60% after reporting encouraging Phase 1/2 trial results for solnerstotug, showing a 14% overall response rate in resistant tumors, significantly exceeding historical rechallenge rates.</li>
</ul>
<ul>
<li>DBV Technologies SA ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) surged 59.85% after securing up to $306.9 million in financing for its Viaskin peanut patch program, including $125.5 million upfront and potentially $181.4 million from warrant exercises.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.06% to hover around $69.88 per barrel.
Gold Spot US Dollar advanced 0.47% to hover around $3,071.22 per ounce. Its fresh record high stood at $3,086.08 per ounce.
Asian markets closed on a lower note on Friday. China&#8217;s CSI 300, India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, South Korea's Kospi, and Japan's Nikkei 225 index declined, whereas Australia's ASX 200 index rose. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44528015/trump-reacts-to-selloff-following-auto-tariffs-that-can-take-care-of-itself-in-one-day-two-days-or-o">Trump Reacts To Selloff Following Auto Tariffs: &#8216;That Can Take Care Of Itself In One Day, Two Days, Or One Week&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Analyst Ratings

ETFs

BRZE

DRCT

KPLT

LULU

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

Porsche Automobil Holding SE Stuttgart Pref No VTG RTS

POAHF

VRNT

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin&#xAE; Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
<ul>
<li>DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants</li>
<li>DBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA) for the Viaskin&#xAE; peanut patch in children 4 – 7-years-old and commercial launch, if approved</li>
<li>DBV will host an investor conference call on Monday, March 31st at 5:00pm ET (23h00 CET) to discuss the financing and FDA update</li>
</ul>

Reported Earlier, DBV Technologies Secures Up to $306.9M In Financing To Propel FDA Submission And Potential U.S. Launch Of Viaskin Peanut Patch

<h3>Gainers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 75.8% to $1.19 during Tuesday's after-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 24.07% to $0.67. The company's market cap stands at $2.9 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 9.46% to $4.51. The market value of their outstanding shares is at $92.5 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 8.68% to $0.06. The market value of their outstanding shares is at $1.5 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares moved upwards by 6.43% to $1.22. The company's market cap stands at $22.9 million. </li>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares rose 5.9% to $13.8. The market value of their outstanding shares is at $750.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares fell 25.0% to $0.15 during Tuesday's after-market session. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock fell 19.52% to $2.31. The market value of their outstanding shares is at $297.2 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares declined by 12.27% to $3.29. The market value of their outstanding shares is at $10.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock declined by 10.21% to $4.4. The company's market cap stands at $5.7 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares fell 8.57% to $2.67. The market value of their outstanding shares is at $3.7 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares fell 8.15% to $0.9. The company's market cap stands at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

BCAX

CAPS

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

GLTO

HUMA

KAPA

PLRZ

PTPI

TNON

12 Health Care Stocks Moving In Tuesday's After-Market Session

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin&#xAE; Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1
<ul>
<li>COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required</li>
<li>FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old</li>
<li>VITESSE topline results on-track for the fourth quarter of 2025</li>
<li>BLA submission for Viaskin peanut patch in children 4 – 7-years-old is now expected in the first half of 2026; DBV anticipates this path may accelerate potential launch, if approved by the FDA, by approximately one year</li>
<li>DBV also reports unaudited financial results1 for the full year 2024, including cash and cash equivalents</li>
</ul>

DBV Technologies Reaches FDA Agreement To Use VITESSE Data For Viask In Peanut Patch BLA In 4–7-Year-Olds, Accelerating Filing To 1H 2026

Citizens Capital Markets analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $10 price target.

Price Target

Reiteration

Citizens Capital Markets Reiterates Market Outperform on DBV Technologies, Maintains $10 Price Target

<h3>Gainers</h3>
<ul>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares rose 92.1% to $4.61 during Tuesday's pre-market session. The company's market cap stands at $28.8 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 55.15% to $0.43. The company's market cap stands at $5.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 25.65% to $1.91. The market value of their outstanding shares is at $26.1 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) shares increased by 20.53% to $1.35. The market value of their outstanding shares is at $57.6 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 14.15% to $1.21. The company's market cap stands at $144.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 13.3% to $4.6. The market value of their outstanding shares is at $94.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares declined by 23.3% to $0.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock decreased by 19.35% to $3.21. The market value of their outstanding shares is at $178.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock fell 18.23% to $0.52. The company's market cap stands at $23.1 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 12.36% to $4.4. The company's market cap stands at $39.2 million. </li>
<li>Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) stock declined by 12.34% to $12.01. The market value of their outstanding shares is at $420.3 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares fell 12.34% to $0.42. The company's market cap stands at $23.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

AZTR

EVAX

FHTX

HCWB

ICCC

IVVD

OMGA

ORKA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024:
<ul>
<li>266,868 DBV Technologies shares,</li>
<li>€ 106,930.51.</li>
</ul>
When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
<ul>
<li>41,159 DBV Technologies shares,</li>
<li>€ 432,367.25.</li>
</ul>
Over the period from July 1, 2024, to December 31, 2024, the following transactions were executed:
<ul>
<li>1682 buy transactions,</li>
<li>1800 sales transactions.</li>
</ul>
Over this same period, the volumes traded represented:
<ul>
<li>404,081 shares and € 296,390.97 on purchases,</li>
<li>440,957 shares and € 340,906.76 on sales.</li>
</ul>

DBV Technologies Reports H2 Liquidity Contract Update: 267K Shares, €107K In Account; 1,682 Buy And 1,800 Sales Transactions Covering 404K Shares Purchased, €296K And 441K Shares Sold, €341K

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $10 price target.

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $10 Price Target

DBV Technologies shares are trading higher after the company announced 3-year results from its IPITOPE Phase 3 open-label extension study.

<ul>
<li>EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN&#xAE; Peanut patch in toddlers 1 – 3 years through 36 months</li>
<li>68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12</li>
<li>No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE &nbsp;&nbsp;</li>
<li>DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FDA</li>
<li>DBV to highlight these data in multiple abstract presentations at the Eastern Food Allergy &amp; Comorbidity Conference, January 9-12, in Palm Beach, Florida
<ul>
<li>Company to host investor webcast today at 5:00pm ET</li>
</ul>
</li>
</ul>

Biotech

General

DBV Technologies Announces  3-Year Results from EPITOPE Phase 3 Open-Label Extension Study; Data Provided Support That Continued Treatment With VIASKIN Peanut Showed Improveemntn Through 36 Months Of Treatment Across All Efficacy Parameters

On Wednesday, DBV Technologies SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42447895/dbv-confirms-alignment-with-u-s-fda-on-accelerated-approval-pathway-for-the-viaskin-peanut-patch-i" rel="noreferrer noopener">toddlers aged 1–3 years</a>.
The FDA has outlined a clear Accelerated Approval pathway for the therapy, offering a streamlined regulatory process for <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33487292/dbv-technologies-advances-peanut-allergy-program-with-fda-support-on-pediatric-studies" rel="noreferrer noopener">peanut allergy treatment</a>.
The FDA confirmed that the Viaskin Peanut patch satisfies the key criteria for Accelerated Approval, including addressing a serious condition and offering a meaningful advantage over existing therapies.
The FDA also acknowledged that efficacy data from DBV's Phase 3 EPITOPE study meets the requirement of an intermediate clinical endpoint reasonably predicting clinical benefits.
The pivotal decision reduces regulatory uncertainty and allows DBV to concentrate on completing essential studies.
To meet FDA requirements for Accelerated Approval, DBV will conduct a post-marketing confirmatory study using the commercial version of the Viaskin Peanut patch.
This study will validate the safety and efficacy of the redesigned patch, which features improvements for ease of use and identification without altering skin contact components. The confirmatory study will include a double-blind, placebo-controlled food challenge and aims to support the Biologic License Application (BLA) for toddlers aged 1–3 years.
The ongoing COMFORT Toddlers trial will complement these efforts.
This Phase 3 study will evaluate safety, adhesion, and efficacy in approximately 480 participants across multiple regions. Data from this study will be crucial in DBV's FDA marketing application submission, expected in the second half of 2026.
DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025.
Price Action: DBVT stock is up 14.90% at $3.78 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42460647/ciena-q4-earnings-misses-eps-estimates-margins-decline-names-new-chair" target="_blank" rel="noreferrer noopener">Ciena Q4 Earnings: Profit Misses Expectations, Margins Decline, Names New Chair</a></li>
</ul>

Health Care

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBC Technologies shares are trading higher after the company announced alignment with the FDA on an accelerated approval pathway for the Viaskin peanut patch in toddlers one to three years old.

ADBE: -11% &#x7C; <a href="https://www.benzinga.com//node/42448063">Adobe shares are trading lower following mixed guidance.</a>
&nbsp;
DBVT: 76% &#x7C; <a href="https://www.benzinga.com//node/42448378">DBC Technologies shares are trading higher after the company announced alignment with the FDA on an accelerated approval pathway for the Viaskin peanut patch in toddlers one to three years old.</a>
&nbsp;
ZENA: 41% &#x7C; <a href="https://www.benzinga.com//node/42458190">ZenaTech Announces The Launch Of A Quantum Computing Project For Traffic Optimization And Weather Forecasting Using The Company's Drones</a>

ADBE

ZENA

Market-Moving News for December 12th

U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. The futures of all the four major indices were trading lower.
November inflation data was in line with analyst expectations, shooting up the probability of a further 25 basis point rate cut in December rose to 98.6% versus 58.75% probability a month ago, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>. Federal Reserve officials are currently in a quiet period ahead of their December meeting.
Traders now await the producer price index data, which will be released later today. The 10-year and two-year Treasury notes yielded 4.30% and 4.18%, respectively
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.16%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.18%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.12% to $606.71 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.20% to $528.87, according to <a href="https://www.benzinga.com/pro/">Benzinga Pro data</a>.
Cues From The Last Session
The Consumer Price Index (CPI) for November climbed 2.7% year-over-year, aligning with expectations. 1 Core inflation, excluding volatile food and energy costs, held steady at 3.3%.  
The Magnificent Seven's combined <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42445451/nasdaq-100-rallies-to-record-highs-magnificent-7-market-cap-tops-17-trillion-bitcoin-soars-to-100000-whats-driving-markets-wednesday">market cap hits $18.2 trillion,</a> with five giants reaching all-time highs on Wednesday. The Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>), a closely watched benchmark for the group&#8217;s market performance, surged 3.03% on Wednesday, setting a new all-time high.
The Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>) surged 3.03%, its best performance since early November. 
The broader market also participated in the rally. The S&amp;P 500 climbed 0.82%, nearing its all-time high. Small-cap stocks added 0.48%, while the Dow Jones Industrial Average ended 0.22% lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.77%</td>
<td>20,034.90</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.82%</td>
<td>6,084.19</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.22%</td>
<td>44,148.56</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.48%</td>
<td>2,394.16</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42445451/nasdaq-100-rallies-to-record-highs-magnificent-7-market-cap-tops-17-trillion-bitcoin-soars-to-100000-whats-driving-markets-wednesday">Nasdaq 100 Rallies To Record Highs, Magnificent 7 Market Cap Tops $17 Trillion, Bitcoin Soars To $100,000: What&#8217;s Driving Markets Wednesday?</a>
Insights From Analysts
Despite the S&amp;P 500 Index nearing record highs on Wednesday, its breadth was skewed in the favour of the bears.
&#8220;117 stocks in the S&amp;P 500 made a new monthly low yesterday, the most since 139 on Halloween. 211 made a 10-day low, most since Sept 6,&#8221; said Ryan Detrick, the chief market strategist at Carson Group.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">117 stocks in the S&amp;P 500 made a new monthly low yesterday, the most since 139 on Halloween. 211 made a 10-day low, most since Sept 6. Not end of world stuff, but clearly some deterioration under the surface taking place.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1866927212479590411?ref_src=twsrc%5Etfw">December 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The breadth has been skewed for the last seven days. &#8220;Since 2010, only happened two other times. Aug &#8217;11 and Dec &#8217;18. Small sample size yes, but not the worst times for bulls going forward,&#8221; added Detrick.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">7 consecutive days there have been more decliners than advancers on the S&amp;P 500. Since 2010, only happened two other times. Aug &#39;11 and Dec &#39;18. Small sample size yes, but not the worst times for bulls going forward.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1866929220540305836?ref_src=twsrc%5Etfw">December 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Talking about balancing growth amid policy shifts, Andrew Pease, the chief investment strategist at Russell Investments said, &#8220;Tax cuts and deregulation could provide a meaningful growth boost, particularly to domestic and cyclical sectors.&#8221;
&#8220;Given lower valuations and improving sentiment, we are more positive on U.S. small-cap equity than we have been in prior years. Large-cap dominance in both earnings and price appreciation will require a catalyst to shift returns in the small-cap direction,&#8221; he added.
Apart from small-caps, Pease in his note said that &#8220;growth managers targeting high-growth cyclical sectors like software, while value managers identify mergers and acquisitions potential in financials and healthcare. Core managers are balancing cyclical exposure and managing risks in rate-sensitive sectors.&#8221;
Citing rich valuations, Alex Chaloff, the chief investment officer at Bernstein Private Wealth Management said that they are still pro-equities.
&#8220;We&#8217;re optimistic on equities, think that valuations are a little bit rich in a pocket of the market, but there are some opportunities. In bonds, you can clip the coupon even if rates move higher from here, which we don&#8217;t think is our base case,&#8221; he said.
See Also: <a href="https://www.benzinga.com/24/12/42453807/spacex-hits-350-billion-valuation-in-insider-share-sale-ceo-elon-musk-says-no-investors-wanted-to-sell-shares">SpaceX Hits $350 Billion Valuation In Insider Share Sale: CEO Elon Musk Says &#8216;No Investors Wanted To Sell Shares&#8217;</a>
Upcoming Economic Data
This week&#8217;s remaining economic calendar with essential data releases that will help investors shape their future plans and strategies.
<ul>
<li>On Thursday, initial jobless claims data till Dec. 7 and the core and headline producer price index for November will be released at 8:30 a.m. ET.</li>
<li>On Friday, the import price index data will be released at 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Macy's, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) was down 1.03% as its net sales decreased 2.4%. Sales growth at Macy's First 50 locations, Bloomingdale's, and Bluemercury was offset primarily by weakness in Macy's non-First 50 locations, digital channels, and cold weather categories.</li>
<li>Nordson Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) fell by 5.43% as the company revenue guidance for the fiscal year 2025 was below analyst expectations.</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) declined by 9.99% after its earnings beat estimates but the revenue guidance for the first quarter missed the mark.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) was up 1.08% in the premarket as it is slated to report quarterly earnings before the bell. Wall Street expects it to report quarterly earnings of 66 cents per share on revenue of $1.10 billion.</li>
<li>DBV Technologies SA &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) rose by 32.83% after the company announced alignment with the FDA on an accelerated approval pathway for the Viaskin peanut patch in toddlers one to three years old.</li>
<li>Amplitech Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) gained 39.90% after the company priced its $2.2 million registered direct offering of 1.35 million shares at $1.60 per share.</li>
<li>Nuburu Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) was up 22.62% after the company addressed NYSE compliance violations over 4.6 million share issuance.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) is in focus as President-elect Donald Trump <a href="https://www.benzinga.com/general/social-media/24/12/42454492/djt-stock-in-focus-as-trump-set-to-ring-nyse-bell-today-heres-why-president-elect-once-threatened-to-shift-trump-media-from-nasdaq">is set to ring </a>the New York Stock Exchange opening bell Thursday.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were largely unchanged in the early New York session and rose 0.03% to hover around $70.31 per barrel.
The gold spot index fell by 0.37% to $2,746.59 per ounce. The Dollar Index was down 0.12% to 106.581 level.
Asian markets were mixed on Thursday as Australia&#8217;s ASX 200 and India&#8217;s S&amp;P BSE Sensex declined. While, Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, Japan&#8217;s Nikkei 225, and South Korea&#8217;s Kospi Index advanced. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42454495/microsoft-expects-800-million-impairment-charge-due-to-gms-cruise-exit-but-analysts-say-its-a-step-in-the-right-direction-for-automaker">Microsoft Expects $800 Million Impairment Charge Due To GM&#8217;s Cruise Exit, Analyst Says It&#8217;s A &#8216;Step In The Right Direction&#8217; For Automaker</a></li>
</ul>
Image Via Shutterstock

Movers & Shakers

AMPG

BURU

CIEN

MAGS

NDSN

Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows

Press Releases

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies Announces Plan to Implement ADS Ratio Change

Information regarding the total number of voting rights and   total number of shares of the Company as of November 30, 2024

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Comments

DBV Technologies

Interés en corto

DBV Technologies (NASDAQ:DBVT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL